Although drugs targeting the key molecules or genes of the metabolic pathway, such as glutaminase and HIF-2α, have been developed and applied in clinical trials for RCC, their objective response rate and safety are unsatisfactory [25, 26], highlighting the necessity of our study. This evidence concerns the gene EPAS1 and renal cell carcinoma.